Why LinkedIn (LNKD) Stock Is Lower After Hours

NEW YORK (TheStreet) -- LinkedIn (LNKD) stock is moving lower on Thursday after second-quarter and full-year guidance came in lower than expected. 

After the bell, shares have dropped 2.6% to $157.

The professional social network guided for revenue over the three months to June of between $500 million and $505 million. Full-year guidance is expected between $2.06 billion and $2.08 billion. Analysts forecast second-quarter sales of $505.1 million and full-year sales of $2.11 billion.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates LINKEDIN CORP as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:

"We rate LINKEDIN CORP (LNKD) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, unimpressive growth in net income, disappointing return on equity and premium valuation."

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.


WATCH: More market update videos on TheStreet TV | More videos from Kori Hale

More from Markets

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy